Coiled Therapeutics, previously Roquefort Therapeutics, has completed the acquisition of the exclusive worldwide licence to AO-252 and admitted its shares to trading on the AIM Market of the London Stock Exchange. 

Admission follows a successful fundraise of £8.5 ($11.3) million through the issue of 85,000,000 New Ordinary Share with institutional investors. 

The company has now completed its transition from a pre-clinical platform to a material clinical-stage oncology company focused on precision medicine.  

Its lead asset AO-252 is a first-in-class, orally administered, brain-penetrant small molecule inhibitor targeting TACC3, a validated previously undruggable oncology target.  

In early Phase I data in advanced solid tumours, AO-252 has demonstrated tumour reductions of up to 33% in endometrial and 29% in ovarian cancer patients at sub-therapeutic exposure levels. AO-252 has also shown a favourable benign safety and tolerability profile to date. 

Coiled says expansion of the AO-252 Phase I trial into prostate and ovarian cancers is underway, with material data readouts anticipated by Q4 2026. 

In addition to AO-252, the company is assessing its STAT-6 siRNA programme for a Phase I clinical trial for immunology. 

Dr Sotirios Stergiopoulos, Executive Chairman of Coiled Therapeutics, commented: “We are delighted to have completed the transaction and to begin Coiled Therapeutics’ journey as an AIM quoted company. AO-252 is a first-in-class asset that is already delivering encouraging signals of efficacy in patients with advanced solid tumours who have exhausted all other treatment options.  

“The Fundraise will allow us to drive forward our dual indication strategy, which prioritises the expansion of our Phase I trial into patients with prostate and ovarian cancers. These are areas where patients face a major lack of effective therapies after failing standard treatments. We believe AO-252’s unique ability to target TACC3 and cross the blood-brain barrier offers a potential lifeline for these patients.”